38 results
6-K
EX-10.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Current report (foreign)
5:28pm
).
“Free Writing Prospectus” shall mean a free writing prospectus, as defined in Rule 405.
“Hazardous Materials” shall have the meaning ascribed … preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials
424B5
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Prospectus supplement for primary offering
5:27pm
a website at www.viraxbiolabs.com, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically
424B3
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
20 Dec 23
Prospectus supplement
4:03pm
on a limited number of suppliers or, in many cases, single suppliers, for laboratory equipment and materials and may not be able to find replacements
F-3
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
5 Dec 23
Shelf registration (foreign)
4:06pm
these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained … and materials and may not be able to find replacements or immediately transition to alternative suppliers.
Our suppliers may experience development
D
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
17 Oct 23
$2.15 mm in equity / options / securities to be acquired, sold $2.15 mm, 1 investor
4:05pm
materials under this undertaking or otherwise and can require offering materials only to the
extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.
6-K
EX-10.1
dpekuocz
12 Oct 23
Current report (foreign)
8:00am
6-K
EX-10.1
cuzu5v0
1 Sep 23
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
7:37am
6-K
EX-10.1
oxl0528
8 Nov 22
Virax Biolabs Group Limited Announces $3.8 Million Private Placement
4:56pm
6-K
oytb24iz 04u
8 Nov 22
Virax Biolabs Group Limited Announces $3.8 Million Private Placement
4:56pm
6-K
EX-10.3
sqpja8 1z
8 Nov 22
Virax Biolabs Group Limited Announces $3.8 Million Private Placement
4:56pm
20-F
ybc1k3p
12 Aug 22
Annual report (foreign)
4:20pm
6-K
EX-99.1
e2gvc2b6po2ioo70dxbc
26 Jul 22
Current report (foreign)
7:36am
6-K
EX-1.1
3deq73834r3iub1u3t
26 Jul 22
Current report (foreign)
7:36am
424B4
s62kled8cho qx
21 Jul 22
Prospectus supplement with pricing info
10:01am
FWP
r3e lq1xxggac
30 Jun 22
Free writing prospectus
9:04pm
FWP
jd085ixdhgw
30 Jun 22
Free writing prospectus
1:29pm
F-1/A
hcwbq9xfxtngd0o6kyej
24 Jun 22
Registration statement (foreign) (amended)
9:47pm
F-1/A
0euqafj4slah564vwflb
24 Jun 22
Registration statement (foreign) (amended)
8:21am
F-1/A
EX-1.1
geti28xo60xiu 8w765w
21 Jun 22
Registration statement (foreign) (amended)
6:26am